⚠️ JAN 12 – FEB 6 CYBERATTACK: ALL ORDERS REFUNDED • DO NOT PURCHASE UNTIL FURTHER NOTICE • CONTACT support@anubis.estate FOR REFUND STATUS
Compassionate useAndrogen Modulator

Compound 61493

Formula Pending

Molecular Mass
N/A
CAS Registry
AUTO-061493
Risk Class
MODERATE
Last Audit
Mar 7, 2108

Research Abstract

Androgen Modulator candidate engineered for oncology adjuvant initiatives with automated dossier coverage.

Compound 61493 is a androgen modulator asset inside androgen modulator innovation track initiatives, optimized for oncology adjuvant and inflammation control.

The dossier currently sits in compassionate use with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.

Supply records cite CAS AUTO-061493 with updates logged 2108-03-07.

Acquisition Protocol

Authorized research personnel may request deployment of this compound for laboratory analysis.

Primary Vectors

Oncology adjuvantInflammation control

Nomenclature

CX-61493Androgen Modulator Program 61493

Reference Material

  1. [1] Anubis Compound Registry • CAS AUTO-061493
  2. [2] Operations Pulse • Androgen Modulator innovation track
  3. [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61493